SMAD3 is a transcriptional modulator activated by transforming growth factor β (TGF-β) [66], [67] and has been reported to be marginally associated with coronary artery disease, of which low HDL-C levels is a risk factor [68]. The gene discussed is TGFB1; the disease is coronary artery disorder.